<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The efficacy of post-ischemic treatment with AJ-3941 ((+/-)-(E)-1-(3-fluoro-6,11-dihydrodibenz[b,e]-oxepine-11-yl )-4-(3-<z:chebi fb="1" ids="30396">phenyl</z:chebi>-2- propenyl)-<z:chebi fb="0" ids="28568">piperazine</z:chebi> dimaleate, CAS 143110-70-7), a cerebrovascular selective <z:chebi fb="0" ids="29108">Ca2+</z:chebi> channel <z:chebi fb="68" ids="48706">antagonist</z:chebi>, on <z:e sem="disease" ids="C0751955" disease_type="Disease or Syndrome" abbrv="">brain infarction</z:e> induced by focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-reperfusion in rats was evaluated </plain></SENT>
<SENT sid="1" pm="."><plain>Focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> was induced by transient occlusion of middle cerebral artery (<z:chebi fb="70" ids="34342">MCA</z:chebi>) with a 3-0 nylon monofilament for 90 min </plain></SENT>
<SENT sid="2" pm="."><plain>One day after <z:chebi fb="70" ids="34342">MCA</z:chebi> occlusion (MCAo), brain <z:mpath ids='MPATH_124'>infarct</z:mpath> size was determined by measuring 2,3,5-triphenyltetrazonium <z:chebi fb="76" ids="17996">chloride</z:chebi>-negative stained area of the serial brain sections </plain></SENT>
<SENT sid="3" pm="."><plain>The development of <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e> was observed in both regions of cortex and subcortex, such as striatum, caudatum, putamen, hippocampus and corpus callosum </plain></SENT>
<SENT sid="4" pm="."><plain>Post-ischemic treatment with AJ-3941 (1 or 3 mg/kg p.o., 10 min and 3 h after the occlusion) significantly reduced the <z:mpath ids='MPATH_124'>infarct</z:mpath> size and volume in the ipsilateral hemisphere in a dose-dependent manner, compared to the solvent control </plain></SENT>
<SENT sid="5" pm="."><plain>The reducing effect was observed mainly in the cortical region, and a significant reduction of the subcortical <z:mpath ids='MPATH_124'>infarct</z:mpath> volume was found at the higher dose (3 mg/kg) </plain></SENT>
<SENT sid="6" pm="."><plain>Post-ischemic treatment with the <z:chebi fb="0" ids="15627">thromboxane A2</z:chebi> synthetase inhibitor, <z:chebi fb="199" ids="26708">sodium</z:chebi> ozagrel (150 micrograms/kg/min i.v. infusion, between 1 h and 24 h after the MCAo) did not reduce the <z:mpath ids='MPATH_124'>infarct</z:mpath> volume in the hemisphere after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-reperfusion </plain></SENT>
<SENT sid="7" pm="."><plain>AJ-3941 had only minimum effect on the elevation of body temperature during <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-reperfusion </plain></SENT>
<SENT sid="8" pm="."><plain>These results indicate that post-ischemic treatment with AJ-3941 may ameliorate the brain injury after the transient focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>, and they suggest that AJ-3941 has beneficial effects for treatment of ischemic cerebral damage, such as <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
</text></document>